The biotech sector was on a bumpy ride over the week as shares of Spectrum surged on positive data from a phase II study, while that of Incyte plunged on the failure of melanoma study. In an effort to bolster its presence in the gene therapy space Swiss giant Novartis announced the acquisition of AveXis Inc.
Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться